NCT01635881已完成3 期
EMERGE: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm Percutaneous Transluminal Coronary Angioplasty (PTCA) Dilatation Catheter
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Device Procedural Success
研究概览
简要总结
To evaluate the acute safety and device procedural success of the Emerge 1.20 mm PTCA dilatation catheter when used as a pre-dilatation device in the stenotic portion of coronary arteries or bypass grafts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is ≥ 18 years of age.
- •Subject or a legally authorized representative must provide written informed consent prior to any study related procedures.
- •Subject must agree not to participate in any other clinical study during hospitalization for the index procedure.
- •Subjects must have a single or double vessel coronary artery disease and clinical evidence of ischemic heart disease, such as stable / unstable angina or silent ischemia.
- •Angiographic Inclusion Criteria:
- •Subject must have de novo or restenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention. An embolic protection device must be used in all Saphenous venous grafts (SVG) interventions performed during the index procedure.
- •A maximum of two lesions, including at least one target lesion, in up to two coronary arteries.
- •Target and non-target lesions must be located in different coronary arteries or bypass grafts.
- •Target lesion(s) must have a diameter stenosis of ≥70% by visual estimation and may include chronic total occlusions (CTO)
- •Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success.
排除标准
- •Subject with a known hypersensitivity or contraindication to Aspirin, Heparin, Bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot be adequately pre-medicated.
- •Subject with known diagnosis of an acute myocardial infarction (AMI) within 72 hours prior to index procedure.
- •Subject with known pregnancy or is nursing. Women of childbearing potential should have a documented negative pregnancy test within 7 days before index procedure.
- •Planned or actual target lesion treatment with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure.
- •A serum creatinine level > 2.0 mg/dl within seven days prior to index procedure.
- •Cerebrovascular accident (CVA) within the past 6 months.
- •Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.
- •Subject has a known left ventricular ejection fraction (LVEF) <30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary).
- •Angiographic Exclusion Criteria
- •More than two lesions requiring treatment.
- •Unprotected left main coronary artery disease.
- •Coronary artery spasm of the target vessel in the absence of a significant stenosis.
- •Target lesion with angiographic presence of probable or definite thrombus.
- •Untreated lesions with >50% diameter stenosis remaining in any coronary artery.
- •Target lesion involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch >2.0 mm in diameter.
- •Non-target lesion to be treated during the index procedure meets any of the following criteria:
- •Located within a bypass graft (venous or arterial)
- •Left main location
- •Chronic total occlusion
- •Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent)
- •Treatment not deemed a clinical angiographic success
结局指标
主要结局
Device Procedural Success
时间窗: Peri-procedural
Device procedural success consisting of the following: 1. Successful delivery, inflation, deflation and withdrawal of the study balloon. 2. No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in TIMI flow from baseline related to the study balloon. 3. Final TIMI flow grade of 3 at the conclusion of the percutaneous coronary intervention procedure
次要结局
- In-hospital Major Adverse Cardiac Events (MACE)(Participants will be followed for the duration of hospital stay (an expected average of 24 hours))
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina PectorisRefractory Angina PectorisGene TransferCoronary Artery DiseaseNCT03039751Kuopio University Hospital63
已完成
不适用
Study of Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Combination Coronary CatheterMyocardial InfarctionAtherosclerosisMyocardial IschemiaCoronary Artery DiseaseNCT00901446Infraredx10
撤回
不适用
Evaluation of Luminal Expansion Following Stenting of Femoro-popliteal Occlusive DiseaseFemoropopliteal StenosisNCT01643746Centre hospitalier de l'Université de Montréal (CHUM)
已完成
不适用
ACT DiamondTemp TempeRAture-Controlled and Contact Sensing RF Ablation Clinical Trial for Atrial FibrillationParoxysmal Atrial FibrillationNCT02821351Medtronic Cardiac Ablation Solutions70
已完成
不适用
Percutaneous Transluminal Coronary Angioplasty (PTCA) Registries I, II, and III and the Dynamic RegistryCardiovascular DiseasesCoronary DiseaseHeart DiseasesNCT00005677University of Pittsburgh4,290